The value of cerebrospinal fluid biomarkers for the differential diagnosis of dementia
Faculty of Pharmaceutical, Biomedical and Veterinary Sciences . Biomedical Sciences
Neurodegenerative Disease Management
, p. 211-219
University of Antwerp
The diagnostic markers for Alzheimers disease (AD) (b‑amyloid142, total tau protein and hyperphosphorylated tau) are gradually finding their way into routine clinical practice as an affirmative diagnostic tool, rather than an exclusionary one. Their discriminatory power for the differential diagnosis of dementia is, however, suboptimal and other cerebrospinal fluid biomarkers, especially those that are reflective of the pathology of the non-AD dementia etiologies, could improve the differential dementia diagnosis either by their individual use (diagnostic value) or in combination with the established AD biomarkers (added diagnostic value). Unfortunately, validated biomarkers for non-AD dementias do not yet exist, but promising candidates have been identified over recent years. This review summarizes the current literature on cerebrospinal fluid biomarkers for the diagnosis of AD and other dementias.